Hyojin Kim MD, Abstract Co-Author: Nothing to Disclose

Ji Hyun Koo MD, Presenter: Nothing to Disclose

Junghee Lee PhD, Abstract Co-Author: Nothing to Disclose

Jongmin Shin, Abstract Co-Author: Nothing to Disclose

Jaewon Lee, Abstract Co-Author: Nothing to Disclose

Geun Ho Im, Abstract Co-Author: Nothing to Disclose

In Su Lee, Abstract Co-Author: Nothing to Disclose

00030490-DMT et al, Abstract Co-Author: Nothing to Disclose

Hollow Manganese Oxide Nanoparticles (HMON) is a newly developed T1 contrast agent, which is a nanometer-sized colloid particles with small size and large surface area. To evaluate the effectiveness and the potential of HMON when conjugated with Cetuximab (monoclonal antibody for epidermal growth factor receptor) (HMON-Cetuximab) for targeted MRI and drug delivery in epidermoid cancer of the vulva.

We implanted A431 cells (epidermoid cancer of the vulva) in the proximal femur region of a nude mouse. The HMON (10nm size, specific relaxivity, r1= 1.42, r2= 7.74 S-1mM-1) and HMON-Cetuximab (8 Cetuximab/HMON) were synthesized, which were then intravenously injected (10mg of HMON/kg of body weight) to the mouse (n=3). A time course of MR images were acquired before injection, and 0.5, 1, 3, 6 and 24 hr after injection. Immunohistochemical staining on the tumor tissue was performed.

All the tumors showed iso signal intensity (SI) on T1WI and heterogeneous high SI on T2WI. For both HMON and HMON-Cetuximab injected mice, the tumors showed early, strong and heterogeneous enhancement (~ 3hrs). However, only the portions of the tumor with EGFR activity show the prolonged enhancement (> 6hrs).

HMON conjugated with monoclonal antibody for EGFR, Cetuximab, can be used as a molecular imaging agent for targeted MRI. Within the tumor, the regions with high EGFR activity can be visualized in T1W MRI, which can be utilized for delivery of therapeutic drugs as well as for diagnostic imaging.

HMON conjugated with monoclonal antibody for EGFR, Cetuximab, can be used as a molecular imaging agent for targeted MRI.

Kim, H, Koo, J, Lee, J, Shin, J, Lee, J, Im, G, Lee, I, et al, 0, Hollow Manganese Oxide Nanoparticles (HMON) Conjugated with Cetuximab for Targeted Imaging of the Epidermoid Cancer.  Radiological Society of North America 2009 Scientific Assembly and Annual Meeting, November 29 - December 4, 2009 ,Chicago IL. http://archive.rsna.org/2009/8007955.html